Recall of Omega Pharma Ltd's Napralief 250mg Gastro-Resistant Tablets
Areazine synthesizes this MHRA medicine alert directly from MHRA's official public data feed. See our methodology for full source attribution and refresh cadence.
Omega Pharma Ltd is recalling specific batches of Napralief 250mg Gastro-Resistant Tablets due to missing text in the Patient Information Leaflet and on the carton, affecting product safety information.
What this MHRA medicine alert tells you, and what most readers miss
This notice was issued by MHRA on April 23, 2026 and geographically references United Kingdom. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Medicine Alerts - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, MHRA, medicine.
What Happened
Omega Pharma Ltd is recalling specific batches of Napralief 250mg Gastro-Resistant Tablets due to missing text in Section 2 and Section 3 of the Patient Information Leaflet (PIL) and on the carton.
Which Products Are Affected
The affected products are Napralief 250mg Gastro-Resistant Tablets from specific batches. No model numbers, UPCs, quantities, or date ranges were provided in the source data.
What You Should Do
Consumers should refer to the MHRA website for details on the recall and follow any instructions provided by the agency.
Why This Matters
This recall addresses potential risks from incomplete information, ensuring patients can use the medication safely; it underscores the importance of accurate labeling in pharmaceuticals.
Source
The recall information is attributed to MHRA at https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-omega-pharma-ltd-napralief-250mg-gastro-resistant-tablets-el-26-a-slash-21
Original source: MHRA Official Notice ↗
Related Medicine Alerts
All Medicine Alerts →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this MHRA medicine alert: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (970 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 23, 2026.
Frequently Asked Questions
Common questions about this MHRA medicine alert.